GB0321648D0 - Quinazoline derivatives - Google Patents

Quinazoline derivatives

Info

Publication number
GB0321648D0
GB0321648D0 GBGB0321648.8A GB0321648A GB0321648D0 GB 0321648 D0 GB0321648 D0 GB 0321648D0 GB 0321648 A GB0321648 A GB 0321648A GB 0321648 D0 GB0321648 D0 GB 0321648D0
Authority
GB
United Kingdom
Prior art keywords
quinazoline derivatives
quinazoline
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0321648.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29227164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0321648(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to GBGB0321648.8A priority Critical patent/GB0321648D0/en
Publication of GB0321648D0 publication Critical patent/GB0321648D0/en
Priority to DE602004024420T priority patent/DE602004024420D1/de
Priority to AT04768482T priority patent/ATE450528T1/de
Priority to PCT/GB2004/003936 priority patent/WO2005026152A1/en
Priority to CNA2004800335283A priority patent/CN1882572A/zh
Priority to JP2006526685A priority patent/JP2007505874A/ja
Priority to US10/572,262 priority patent/US20070015743A1/en
Priority to MXPA06002965A priority patent/MXPA06002965A/es
Priority to EP04768482A priority patent/EP1664029B1/en
Priority to BRPI0414486-4A priority patent/BRPI0414486A/pt
Priority to AU2004272351A priority patent/AU2004272351A1/en
Priority to CA002539024A priority patent/CA2539024A1/en
Priority to TW093128079A priority patent/TW200526628A/zh
Priority to ARP040103319A priority patent/AR045752A1/es
Priority to IL174260A priority patent/IL174260A0/en
Priority to ZA200602189A priority patent/ZA200602189B/en
Priority to NO20061320A priority patent/NO20061320L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Structural Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
GBGB0321648.8A 2003-09-16 2003-09-16 Quinazoline derivatives Ceased GB0321648D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0321648.8A GB0321648D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives
CA002539024A CA2539024A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents
AT04768482T ATE450528T1 (de) 2003-09-16 2004-09-14 Chinazolinderivate als antitumormittel
MXPA06002965A MXPA06002965A (es) 2003-09-16 2004-09-14 Derivados de quinazolina como agentes antitumor.
AU2004272351A AU2004272351A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents
PCT/GB2004/003936 WO2005026152A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents
CNA2004800335283A CN1882572A (zh) 2003-09-16 2004-09-14 作为抗肿瘤药物的喹唑啉衍生物
JP2006526685A JP2007505874A (ja) 2003-09-16 2004-09-14 抗腫瘍剤としてのキナゾリン誘導体
US10/572,262 US20070015743A1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents
DE602004024420T DE602004024420D1 (de) 2003-09-16 2004-09-14 Chinazolinderivate als antitumormittel
EP04768482A EP1664029B1 (en) 2003-09-16 2004-09-14 Quinazoline derivatives as antitumor agents
BRPI0414486-4A BRPI0414486A (pt) 2003-09-16 2004-09-14 derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
TW093128079A TW200526628A (en) 2003-09-16 2004-09-16 Quinazoline derivatives
ARP040103319A AR045752A1 (es) 2003-09-16 2004-09-16 Derivados de quinazolina que poseen actividad antitumoral
IL174260A IL174260A0 (en) 2003-09-16 2006-03-12 Quinazoline derivatives as antitumor agents
ZA200602189A ZA200602189B (en) 2003-09-16 2006-03-15 Quinazoline derivatives as antitumor agents
NO20061320A NO20061320L (no) 2003-09-16 2006-03-23 Kinazolinderivater som antitumor agenter

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0321648.8A GB0321648D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives

Publications (1)

Publication Number Publication Date
GB0321648D0 true GB0321648D0 (en) 2003-10-15

Family

ID=29227164

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0321648.8A Ceased GB0321648D0 (en) 2003-09-16 2003-09-16 Quinazoline derivatives

Country Status (17)

Country Link
US (1) US20070015743A1 (enExample)
EP (1) EP1664029B1 (enExample)
JP (1) JP2007505874A (enExample)
CN (1) CN1882572A (enExample)
AR (1) AR045752A1 (enExample)
AT (1) ATE450528T1 (enExample)
AU (1) AU2004272351A1 (enExample)
BR (1) BRPI0414486A (enExample)
CA (1) CA2539024A1 (enExample)
DE (1) DE602004024420D1 (enExample)
GB (1) GB0321648D0 (enExample)
IL (1) IL174260A0 (enExample)
MX (1) MXPA06002965A (enExample)
NO (1) NO20061320L (enExample)
TW (1) TW200526628A (enExample)
WO (1) WO2005026152A1 (enExample)
ZA (1) ZA200602189B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0401646A2 (hu) * 2001-11-03 2004-12-28 Astrazeneca Ab, Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
AU2004272345A1 (en) * 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives
DE602004022180D1 (de) * 2003-09-16 2009-09-03 Astrazeneca Ab Chinazolinderivate
MXPA06002964A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
WO2005118572A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases
WO2006064196A1 (en) * 2004-12-14 2006-06-22 Astrazeneca Ab Pyrazolopyrimidine compounds as antitumor agents
GB0504474D0 (en) * 2005-03-04 2005-04-13 Astrazeneca Ab Chemical compounds
GB0508717D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
JP2009508917A (ja) * 2005-09-20 2009-03-05 アストラゼネカ アクチボラグ 抗癌剤としてのキナゾリン誘導体
US7820683B2 (en) * 2005-09-20 2010-10-26 Astrazeneca Ab 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
ATE443053T1 (de) * 2005-12-02 2009-10-15 Astrazeneca Ab Als inhibitoren von erbb-tyrosinkinase verwendete chinazoleinderivate
EP1957499A1 (en) * 2005-12-02 2008-08-20 AstraZeneca AB 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
EA200901041A1 (ru) 2007-02-06 2010-02-26 Бёрингер Ингельхайм Интернациональ Гмбх Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
JP5336516B2 (ja) 2008-02-07 2013-11-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング スピロ環式複素環化合物、該化合物を含む医薬品、その使用及びその製造方法
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
RU2629116C2 (ru) 2011-10-14 2017-08-24 Эррэй Биофарма Инк. Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
JP5944514B2 (ja) 2011-10-14 2016-07-05 アレイ バイオファーマ、インコーポレイテッド 固体分散体
AR117424A1 (es) * 2018-05-08 2021-08-04 Dizal Jiangsu Pharmaceutical Co Ltd Inhibidores de los receptores erbb

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5538325A (en) * 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4335127A (en) * 1979-01-08 1982-06-15 Janssen Pharmaceutica, N.V. Piperidinylalkyl quinazoline compounds, composition and method of use
GB2160201B (en) * 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
US4921863A (en) * 1988-02-17 1990-05-01 Eisai Co., Ltd. Cyclic amine derivatives
CA1340821C (en) * 1988-10-06 1999-11-16 Nobuyuki Fukazawa Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9702049B1 (pt) * 1996-01-31 2010-08-10 sistema distribuidor contendo dois compartimentos para a dosagem simultánea de duas composições aquosas.
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
US6148197A (en) * 1998-03-06 2000-11-14 Sbc Technology Resources, Inc. Intelligent roaming system with over the air programming
US6384223B1 (en) * 1998-07-30 2002-05-07 American Home Products Corporation Substituted quinazoline derivatives
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
KR20020068261A (ko) * 1999-02-27 2002-08-27 베링거 잉겔하임 파르마 카게 티로신 키나제에 의해 매개되는 신호 변환에 대한 억제효과를 갖는 4-아미노-퀴나졸린 및 퀴놀린 유도체
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
US20020082270A1 (en) * 2000-08-26 2002-06-27 Frank Himmelsbach Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
US6562319B2 (en) * 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
US20040176361A1 (en) * 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
HUP0401646A2 (hu) * 2001-11-03 2004-12-28 Astrazeneca Ab, Tumorellenes hatású kinazolinszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
TW200813014A (en) * 2002-03-28 2008-03-16 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
JP2007500177A (ja) * 2003-07-29 2007-01-11 アストラゼネカ アクチボラグ チロシンキナーゼ阻害剤としてのピペリジルキナゾリン誘導体
GB0317665D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
MXPA06002964A (es) * 2003-09-16 2006-06-14 Astrazeneca Ab Derivados de quinazolina como inhibidores de cinasa de tirosina.
DE602004022180D1 (de) * 2003-09-16 2009-09-03 Astrazeneca Ab Chinazolinderivate
EP1664028A1 (en) * 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives as tyrosine kinase inhibitors
ATE353888T1 (de) * 2003-09-19 2007-03-15 Astrazeneca Ab Chinazolinderivate
EP1670786A1 (en) * 2003-09-25 2006-06-21 Astrazeneca AB Quinazoline derivatives
GB0322409D0 (en) * 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) * 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
WO2005118572A1 (en) * 2004-06-04 2005-12-15 Astrazeneca Ab Quinazoline derivatives as erbb receptor tyrosine kinases

Also Published As

Publication number Publication date
EP1664029B1 (en) 2009-12-02
EP1664029A1 (en) 2006-06-07
AU2004272351A1 (en) 2005-03-24
ATE450528T1 (de) 2009-12-15
JP2007505874A (ja) 2007-03-15
NO20061320L (no) 2006-04-26
DE602004024420D1 (de) 2010-01-14
ZA200602189B (en) 2007-11-28
US20070015743A1 (en) 2007-01-18
CN1882572A (zh) 2006-12-20
MXPA06002965A (es) 2006-06-14
IL174260A0 (en) 2006-08-01
TW200526628A (en) 2005-08-16
CA2539024A1 (en) 2005-03-24
WO2005026152A1 (en) 2005-03-24
BRPI0414486A (pt) 2006-11-14
AR045752A1 (es) 2005-11-09

Similar Documents

Publication Publication Date Title
GB0322409D0 (en) Quinazoline derivatives
IL174534A0 (en) Quinazoline derivatives
GB0321648D0 (en) Quinazoline derivatives
IL174284A0 (en) Quinazoline derivatives
IL174257A0 (en) Quinazoline derivatives
GB0215823D0 (en) Quinazoline derivatives
PT1847539E (pt) Derivados de quinazolina
ZA200702877B (en) Quinazoline derivatives
GB0317665D0 (en) Qinazoline derivatives
PL1682493T3 (pl) Pochodne amidoacetonitrylu
IL174390A0 (en) Quinazoline derivatives
GB0326459D0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PL1706373T3 (pl) Pochodne amidoacetonitrylu
GB2410025B (en) Quinazolin-4-one derivatives
ZA200603039B (en) Quinazoline derivatives
PL374817A1 (en) Quinazoline derivatives
GB0321620D0 (en) Quinazoline derivatives
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0322535D0 (en) Quinazoline derivatives
GB0322534D0 (en) Quinazoline derivatives
GB0309008D0 (en) Quinazoline derivatives
GB0312897D0 (en) Quinazoline derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)